Muutke küpsiste eelistusi

Biomarkers for Alzheimers Disease Drug Development Second Edition 2024 [Kõva köide]

  • Formaat: Hardback, 347 pages, kõrgus x laius: 254x178 mm, 49 Illustrations, color; 2 Illustrations, black and white; XII, 347 p. 51 illus., 49 illus. in color., 1 Hardback
  • Sari: Methods in Molecular Biology 2785
  • Ilmumisaeg: 02-Mar-2024
  • Kirjastus: Springer-Verlag New York Inc.
  • ISBN-10: 1071637738
  • ISBN-13: 9781071637739
Teised raamatud teemal:
  • Kõva köide
  • Hind: 159,88 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Tavahind: 188,09 €
  • Säästad 15%
  • Raamatu kohalejõudmiseks kirjastusest kulub orienteeruvalt 2-4 nädalat
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Lisa soovinimekirja
  • Formaat: Hardback, 347 pages, kõrgus x laius: 254x178 mm, 49 Illustrations, color; 2 Illustrations, black and white; XII, 347 p. 51 illus., 49 illus. in color., 1 Hardback
  • Sari: Methods in Molecular Biology 2785
  • Ilmumisaeg: 02-Mar-2024
  • Kirjastus: Springer-Verlag New York Inc.
  • ISBN-10: 1071637738
  • ISBN-13: 9781071637739
Teised raamatud teemal:
This fully updated volume provides an up-to-date and comprehensive overview of the current state of technologies helping to accelerate Alzheimer’s disease drug development. Addressing the latest advances in preclinical and clinical research, including new insights into the molecular mechanisms and emerging therapeutic strategies, the book continues by exploring digital biomarkers and advanced neuroimaging analysis which will transform how clinical trials in the Alzheimer’s disease field are performed. Written for the highly successful Methods in Molecular Biology series, chapters feature the kind of detailed implementation advice that leads to greater success in the lab or clinic. 

Authoritative and practical, Biomarkers for Alzheimer’s Disease Drug Development, Second Edition seeks to inspire and inform future efforts to develop effective treatments for this devastating disease.
Blood-Based Biomarkers for Early Alzheimers Disease Diagnosis in
Real-World Settings.- Alzheimers Disease Prevention and Treatment Based on
Population-Based Approaches.- CSF N-Glycomics Using High Throughput UPLC-ESI
Techniques in Alzheimers Disease.- CSF N-Glycomics Using MALDI MS
Techniques.- Optimized Pre-Analytical Handling Protocol for Blood-Based
Biomarkers of Alzheimers Disease.- Mass Spectrometry-Based Metabolomics
Multi-Platform for Alzheimers Disease Research.- Analysis of Resting-State
Functional Magnetic Resonance Imaging in Alzheimer's Disease.- Diffusion
Tensor Imaging in Alzheimers Studies.- Magnetic Resonance Spectroscopy (MRS)
in Alzheimers Disease.- Neuroimaging Methods for MRI Analysis in CSF
Biomarkers Studies.- Amyloid PET Imaging: Standard Procedures and
Semiquantification.- PET Imaging to Measure Neuroinflammation In Vivo.-
Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer
PET Approach.- High-Throughput Lipidomics and Metabolomics Profiling for
Brain Tissue and Biofluid Samples in Neurodegenerative Disorders.-
Neuropathological Assessment as an Endpoint in Clinical Trial Design.-
Non-Invasive Visualization of Amyloid-Beta Deposits in Alzheimers
Amyloidosis Mice via Fluorescence Molecular Tomography Using Contrast Agent.-
Brain Banking in Dementia Studies.- Speech-Based Digital Biomarkers for
Alzheimers Research.- cCOG Web-Based Cognitive Assessment Tool.- In Silico
Models to Validate Novel Blood-Based Biomarkers.